Life sciences professionals are grappling with issues related to integrating AI into clinical trials, patient care, and other processes.

How can we ensure that AI models consistently produce accurate and reliable results? What steps should organizations take to ensure the quality of the data used to train and refine AI models? How will AI impact interactions between drug developers on the one hand and the FDA, IRBs and ethics committees on the other? These are just some of the questions Reed Smith attorneys Nancy Halstead and Sarah Thompson Schick address in a new video that is part of our
AI explained Series.

himself

This article is for informational purposes only and does not constitute legal advice.